PARP Inhibitor Maintenance Therapy after Initial Chemotherapy for Advanced Ovary, Fallopian Tube and Primary Peritoneal Cancers

Tune in for a 30-minute discussion of PARP maintenance after initial chemotherapy. This podcast discusses four trials examining the use of PARP inhibitors with initial chemotherapy that have recently been reported. These include:
  • SOLO-1 that examines 2 years of olaparib maintenance in patients with BRCA mutations who responded to initial chemotherapy
  • PAOLA-1 that examines the addition of olaparib maintenance to bevacizumab maintenance in patients who were treated with chemotherapy and bevacizumab
  • PRIMA that examines niraparib maintenance after completion of initial chemotherapy for high risk patients
  • VELIA that examines the use of veliprib with initial chemotherapy alone or with initial chemotherapy and as maintenance.

Podcast released in May 2020. 

Keywords: BRCA, Clinical trial, Genetics, Chemotherapy, Maintenance therapy, PARPi, Pharmacology, Ovary, Molecular profile, Targeted, Homologous Recombination deficient

Target Audience

Physicians, Trainees, Residents, Fellows, APPs
Course summary
Course opens: 
Course expires: 


Please login or register to take this course.